Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma

Contact:

NCT Number:

Protocol:

AAAQ9194

Study Status:

Active/Enrolling

Population:

Adult

Phase:

II

motherapy can improve survival in patients with metastatic adrenal cortical carcinoma.

Are you Eligible? (Inclusion Criteria)

  • * Histologically proven ACC with the majority of disease confined to the
  • peritoneal
  • cavity and resectable; or disease that in the opinion of the investigators
  • can be managed medically or surgically and does not present an immediate
  • threat to the patient’s life.
  • * Disease evaluable by CT or PET imaging
  • * All disease should be deemed resectable based on imaging studies e.g.:
  • - Hepatic metastases (unilateral or bilateral ≤5 lesions, ≤15 cm
  • total diameter)
  • Note: Hepatic lesions must be amenable to complete resection
  • - Primary peritoneal metastases (small disease load ≤P2 disease)
  • without intestinal obstruction.
  • - Lung metastases (≤3 unilateral/bilateral, 9 cm total diameter)
  • Note: lung lesions must be amenable to complete resection.
  • Note: Patients with both pulmonary and hepatic metastases will be
  • enrolled at the discretion of the PI
  • Note: In situations where resection to Completeness of
  • Cytoreduction Score (CC) 0 or 1 is uncertain, patients may
  • undergo diagnostic laparoscopy prior to
  • enrollment to determine feasibility of resection. (Appendix D:
  • Completeness of Cytoreduction Score)
  • * Greater than or equal to 18 years of age
  • * Able to understand and sign the Informed Consent Document
  • * Clinical performance status of ECOG ≤2
  • * Life expectancy of greater than three months
  • * Patients of both genders must be willing to practice birth control
  • during and formfour months after receiving chemotherapy
  • * Hematology:
  • - Absolute neutrophil count greater than 1500/mm3 without the
  • support of filgrastim.
  • - Platelet count greater than 75,000/mm3
  • - Hemoglobin greater than 8.0 g/dl.
  • * Chemistry:
  • - Serum creatinine less than or equal to 1.5 mg/dl unless the
  • measured
  • creatinine clearance is greater than 60 mL/min/1.73 m2
  • - Serum AST and ALT within 5 times the upper limit of normal and
  • a total define the upper limit of grade 2 treatment related

Principal Investigator

Profile Headshot
  • Medical Director, Milstein Hospital HS Surgical Oncology Unit

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032